Article PDF
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Disclosures
PW, WCD, KHC, CHN, PDR, and BL have contracted research with Agendia Inc. PW serves on the advisory board of Medtronic, Lumicell, ImpediMed, Cianna Medical, Prelude, and Bard Bard; has contracted research with Invitae, Intact, Prelude; has ownership interests in Targeted Medical Education, Reverse Medical, Rebound Medical, Lazarus, Cerebrotech, and Medneon; receives honoraria from Medtronic; and has received travel/accommodations from ImpediMed. JVP receives honoraria as part of Speaker’s Bureau for Agendia Inc. WCD has ownership interests in Shaga Medical, LLC. SW, ARM, EBY, CF, KC, LEB, and WA are non-commercial employees of Agendia Inc. No other disclosures have been reported.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Whitworth, P., Beitsch, P.D., Pellicane, J.V. et al. ASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer. Ann Surg Oncol 29, 4153–4154 (2022). https://doi.org/10.1245/s10434-022-11711-0
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-11711-0